• Data are from a formal meta-analysis of 11 eligible studies conducted between 1987 and 2000 in 2,749 patients1
  • CIS outcomes were only documented in 4 studies, and the number of patients was too small for a formal analysis1
  • Overall, the median follow-up was 26 months1

  • Data are from a retrospective chart review of 2,554 patients with BCG-unresponsive NMIBC, which included patients from various countries, including 600 patients from the US4
Most intravesical instillations have a maximum of 2 hours of direct drug contact with cancer in the bladder and require patients to hold treatment in for 1-2 hours5,6
  • Premature voiding of intravesical fluids may not be avoided5,6
ABOUT INLEXZO™
AUA, American Urological Association; BCG, Bacillus Calmette–Guérin; HR, high-risk; NCCN, National Comprehensive Cancer Network; NMIBC, non–muscle invasive bladder cancer; RC, radical cystectomy; SUO, Society of Urologic Oncology.
*RC is “recommended” in the AUA/SUO NMIBC Guideline and “preferred” in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®).2,3
References: 1. Böhle A, Jocham D, Bock PR. Intravesical bacillus Calmette–Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol. 2003;169(1):90-95. doi:10.1016/S0022-5347(05)64043-8 2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Bladder Cancer. V.3.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed January 20, 2026. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 3. Holzbeierlein JM, Bixler BR, Buckley DI, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO Guideline. J Urol. 2024;211(4):533-538. doi:10.1097/JU.0000000000003846 4. Chun DS, Broughton E, Gooden K, Mycock K, Rajkovic I, Taylor-Stokes G. Reasons for non-surgical management of patients with bacillus Calmette–Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC). Poster presented at: 21st Annual Meeting Society of Urologic Oncology; December 2-4, 2020. Poster 44. 5. Anktiva® [Prescribing Information]. Culver City, CA: ImmunityBio, Inc. 2024. 6. Adstiladrin® [Prescribing Information]. Kastrup, Denmark: Ferring Pharmaceuticals. 2025.